长春瑞滨联合顺铂二线治疗晚期乳腺癌临床疗效分析

Vinorelbine and cisplatin as second-line chemotherapy for advanced breast cancer patients

目的观察长春瑞滨联合顺铂二线治疗晚期乳腺癌的疗效和不良反应。方法收集经紫杉类和/或蒽环类化疗后复发晚期乳腺癌病人39例,应用长春瑞滨联合顺铂方案化疗。用药方案：长春瑞滨25mg/m^2静脉滴注,d1、8,顺铂75mg/m^2,静脉滴注,分割为2-4d,21d为1周期。按照WHO实体瘤疗效评价标准近期疗效评估,同时按照NIH CTC 3.0版标准进行毒性分级。结果 39例患者均进行了疗效评价,CR1例,PR20例,SD10例,PD8例,总有效率为53.8%,既往应用紫杉类和/或蒽环类药物对疗效无明显影响（P〉0.05）,主要不良反应为白细胞减少和恶心呕吐。无治疗相关性死亡。结论长春瑞滨联合顺铂治疗二线治疗晚期乳腺癌疗效确定,不良反应可耐受。

Objective To evaluate the antitumor efficacy and toxicity of vinorelbine and cisplatin combination in patients with metastatic breast cancer previously treated with docetaxel and anthracyclines. Methods Thirty - nine patients with recurrent metastatic breast cancer with previous exposure to docetaxel and anthracycline treatment were received vinorelbine 25mg/m^2 on day 1 and 8, followed by cisplatin 75mg/m^2 in 2-5 days. All the patients were assessed for the efficacy and toxicity. Results One patient achieved a complete response and twenty patients achieved a partial response with response rate of 53.8%. Stable disease （SD） was observed in 10 patients （9%）, 8 patients had progressive disease（PD）. There were no significantly different in efficacy between the patients previously treated with docetaxel and anthracyclines（ P 〉0.05 ）. The main toxicity was leucopenia and nausea and vomiting. There were no treatment related deaths. Conclusion The vinorelbine and cisplatin regimen is active in patients with advanced breast cancer who failed docetaxel and anthracyclines and well tolerated.